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Abstract
In humans, defects in lipid metabolism are associated with a number of severe diseases such as atherosclerosis, obesity and
type II diabetes. Hypercholesterolemia is a primary risk factor for coronary artery disease, the major cause of premature
deaths in developed countries. Statins are inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the key enzyme
of the sterol synthesis pathway. Since yeast Saccharomyces cerevisiae harbours many counterparts of mammalian enzymes
involved in lipid-synthesizing pathways, conclusions drawn from research with this single cell eukaryotic organism can be
readily applied to higher eukaryotes. Using a yeast strain with deletions of both HMG1 and HMG2 genes (i.e. completely
devoid of HMGR activity) with introduced wild-type or mutant form of human HMGR (hHMGR) gene we investigated the
effects of statins on the lipid metabolism of the cell. The relative quantification of mRNA demonstrated a different effect of
simvastatin on the expression of the wild-type and mutated hHMGR gene. GC/MS analyses showed a significant decrease of
sterols and enhanced conversion of squalene and sterol precursors into ergosterol. This was accompanied by the
mobilization of ergosterol precursors localized in lipid particles in the form of steryl esters visualized by confocal
microscopy. Changes in the level of ergosterol and its precursors in cells treated with simvastatin depend on the mutation
in the hHMGR gene. HPLC/MS analyses indicated a reduced level of phospholipids not connected with the mevalonic acid
pathway. We detected two significant phenomena. First, cells treated with simvastatin develop an adaptive response
compensating the lower activity of HMGR. This includes enhanced conversion of sterol precursors into ergosterol,
mobilization of steryl esters and increased expression of the hHMGR gene. Second, statins cause a substantial drop in the
level of glycerophospholipids.
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Introduction
Hypercholesterolemia is a primary risk factor for coronary artery
disease, the major cause of premature death in developed countries.
Lowering serum cholesterol levels has proved to be highly effective
for cardiovascular risk reduction. Since cholesterol is synthesized by
the mevalonate pathway, statins – inhibitors of the key enzyme of
this pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase
(HMGR), (P04035, P12683, P12684) – are now the most prescribed
class of drugs worldwide [1,2]. Statin therapy is regarded as well
tolerated. Moreover, beside lowering the level of serum cholesterol,
it has other positive effects such as those involved in improving the
endothelial function, enhancing the stability of atherosclerotic
plaques, decreasing oxidative stress and inflammation, and
inhibiting the thrombogenic response [3]. However, serious adverse
effects have been reported. Myopathy is of particular concern
because of potential rhabdomyolysis. High-dose statin therapy may
be hepatotoxic and may cause peripheral neuropathy, and it has
also been postulated that it can promote tumor growth, particularly
in women [4–7].
The high degree of conservation of the cellular lipid metabo-
lism – from unicellular organisms to human cells – provides an
excellent possibility to use yeast Saccharomyces cerevisiae for studying
the general principles of these processes. Dissecting the pathways
of lipid synthesis, storage and mobilization, as well as related
regulatory processes, in the yeast model may contribute to the
development of therapeutics and drugs against atherosclerosis,
type II diabetes, obesity and other diseases related to dysfunctions
of the lipid metabolism in humans.
In both yeast and humans the mevalonate pathway begins with
the synthesis of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)
from acetyl-CoA. HMGR then converts HMG-CoA to mevalo-
nate which is finally transformed into sterols. The human genome
contains a single gene encoding an HMG-CoA reductase, whereas
yeast (S. cerevisiae) cells contain two genes for this enzyme,
designated HMG1 and HMG2. Human and yeast reductases
demonstrate functional and topological conservation. The se-
quences encoding the active site (COOH-terminal domain) of the
human enzyme and the two yeast isozymes are very similar.
Expression of the human HMG reductase in yeast cells restores
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viability of an hmg1D hmg2D double mutant, proving that the
human reductase provides sufficient catalytic function to replace
both yeast isozymes [8].
Research on statins concentrates mainly on the influence of
statins on endogenous cholesterol biosynthesis, on the level of
atherogenic low-density lipoproteins, and on the serum cholesterol
level [1,9]. Much less is known about the effects of statins on the
lipid metabolism of individual cells. Additionally, data analyzing
the impact of HMGR inhibition on the synthesis of lipids not
connected with the mevalonate pathway, such as glyceropho-
spholipids is scarce. In a previous study [10] we demonstrated that
yeast may be used as a model to investigate the expression of wild-
type and mutated forms of the human HMGR (hHMGR) gene.
Moreover, the system proposed allowed us to investigate the effects
of different statins and different forms of the hHMGR protein
(wild-type or mutated) on the viability and growth rate of yeast
cells.
In the study presented here, we investigated the impact of
simvastatin treatment on the metabolism of sterols and glycer-
ophospholipids within the cell, as well as on the expression of the
hHMGR gene.
Methods
Ethics Statement
No, an ethics statement is not required for this work.
Functional replacement of yeast HMG1 and HMG2 by
wild-type and mutated forms of the hHMGR gene
The yeast strains Y06733 (MATa his3D1 leu2D0 met15D0
ura3D hmg1::kanMX4) and Y16054 (MATa his3D1 leu2D0
lys2D0 ura3D hmg2::kanMX4) (EUROSCARF) were used in this
study. The media as well as the genetic and microbiological
techniques were essentially as in Rose et al. [11]. Simvastatin was
extracted from ZocorH tablets (MERCK & CO, INC, Whitehouse
Station, NJ, USA) by dissolving in pH 7.0 buffer containing 0.5%
dodecyl sodium sulfate in 0.01 M sodium phosphate according to
The United States Pharmacopoeia USP 26. The 10 mg/ml stock
solution of simvastatin was stored at 220uC. Yeasts were cultured
in synthetic media with or without 100 mM simvastatin for 24 h or
48 h.
The cDNA encoding hHMGR gene was amplified by PCR with
the following primers: HMG-F 59-TCTGGAGGATCCAAG-
GATTCTG and HMG-R 59-ACCAAGTGGCTGTCTCAGT-
GAT, and was cloned into pGEM-T Easy (Promega, USA). The
resulting plasmid was digested with BamHI and EcoRI, and the
fragment obtained was inserted into the BamHI-EcoRI sites of the
pUG36 yeast expression vector. The final plasmid encodes the
wild-type hHMGR gene fused to an N-terminal yeGFP (yeast
enhanced green fluorescent protein) tag, under the control of the
yeast MET25 promoter.
The overlap extension PCR according to Ho et al. [12] was
used to introduce the point mutation: GRT (Q766H), into the
hHMGR gene. This mutation was created to induce structural
changes in the catalytic domain of the enzyme but without loss of
its activity.
To construct a diploid strain heterozygous for the hmg1D and
hmg2D mutations, transformation was performed with the pUG36
vector carrying the wild-type hHMGR gene, sporulated and
dissected on complete or minimal medium. After tetrad analysis,
a haploid spore clone was selected that was both kanamycin-
resistant and auxotrophic for histidine – i.e. it carried both
deletions. This strain, termed MB03-1D, required the plasmid-
encoded hHMGR gene for viability.
Determination of mRNA levels
Inocula of S. cerevisiae cells expressing the wild-type or mutated
hHMGR gene were added to liquid minimal media supplemented
with either simvastatin or buffer. The cells were grown with
shaking at 30uC and collected after 24 and 48 h.
Total RNA was isolated from yeast cells using the RNeasy
Mini Kit (QIAGEN, Germany). Reverse transcription (RT) was
performed in duplicate using the QuantiTect Reverse Transcrip-
tion Kit (QIAGEN, Germany), according to the manufacturer’s
recommendations. QPCR amplification was performed using a
LightCycler 1.5 and the LightCycler FastStart DNA Master SYBR
Green I (Roche Diagnostics GmbH, Germany) according to the
manufacturer’s instructions. The Pfaffl model [13] and the relative
expression software tool (REST-384 ) [14] were used to estimate
the relative changes in mRNA levels of hHMGR in the analyzed
strains cultured with or without simvastatin. Data normalization
was carried out versus the transcript of the housekeeping 35S
rRNA. The sequences of all primers and the qPCR amplification
parameters are available upon request.
Confocal microscopy
Cells were cultured overnight. The media were then supple-
mented with either 100 mM simvastatin or buffer and the cells
were further grown with shaking for two hours at 30uC. To
localize neutral lipids and glycerophospholipids in yeast cells, Nile
Red staining was performed as described by Greenspan [15].
Briefly, 1.5 ml of cell culture were centrifuged at 2006g and
resuspended in 500 ml PBS (150 mM NaCl and 20 mM sodium
phosphate buffer, pH 8.0). To this PBS cell suspension, 5 ml of
1 mg/ml Nile Red solution (9-diethylamino-5H-benzo[a]phenox-
azine-5-one, Sigma Chemical Co) in dimethyl sulphoxide (DMSO)
were added and mixed. The cells were harvested by centrifugation
at 2006g, washed twice with PBS and resuspended in 300 ml PBS
for microscope analyses. They were plated on microscope glass
slides and subjected to confocal laser scanning microscopy in the
Laboratory of Confocal and Fluorescence Microscopy, Institute of
Biochemistry and Biophysics, PAS. An EZ-C1 (Nikon) Eclipse
TE2000-E microscope, equipped with a Plan Apo 60X oil
objective (NA 1.4) was used. Excitation of neutral lipids was with
an Argon-Ion laser at 488 nm, and emission was detected at
515/30 nm. Excitation of glycerophospholipids was at 543 nm,
and emission was detected with a 610 LP filter. Images were
collected with a EZ-C1 Confocal v. 3.6 program (Nikon) and
processed with the EZ-C1 Viewer v. 3.6 (Nikon) and Adobe
Photoshop 8.0.
Lipid extraction
Yeast cells were harvested, washed with water, centrifuged, and
their wet weight was estimated. Lipids were extracted according to
the method of Folch [16] with some modifications. The cells were
homogenized and suspended in chloroform : methanol (2:1) to a
final volume equal to 20 times the volume of the cells. After
dispersion, the mixture was agitated for 8 h at room temperature.
The homogenate was centrifuged to recover the lipid phase. The
organic solvent containing the lipids extracted was washed three
times with 1/5 volume of 10 mM EDTA in 0.9% NaCl and
evaporated to dryness in a nitrogen stream and suspended in
hexane or benzene.
Alkaline hydrolysis of lipids
Lipids extracted from yeast cells, suspended in benzene, were
hydrolyzed at 95uC for 2 hours in a mixture of ethanol : H2O
(17:3) containing 15% KOH (w/v). Lipophilic products were
Statins Change Cell Metabolism
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8499
extracted with diethyl ether, washed with water, evaporated to
dryness in a nitrogen stream, suspended in hexane and subjected
to further analyses.
TLC lipid analysis
Lipids were analyzed on Silica gel 60 F254 plates in the following
solvent systems: A, chloroform : methanol : water (65:25:4); B,
toluene : ethyl acetate (95:5). Glycerophospholipids were separated
by two-dimensional chromatography, the 1st dimension being
chloroform : methanol : 28% ammonium hydroxide (42:18:3), and
the 2nd dimension chloroform : methanol : acetone : acetic acid :
water (28:12:12:6:1). Lipids were visualized with iodine vapor.
GC/MS analysis of sterols
GC/MS analysis of sterols was performed without derivatization
on an HP6890N gas chromatograph (Agilent Technologies),
coupled with a GCT Premier mass spectrometer (Waters/
Micromass) equipped with a time-of-flight detector and an electron
ionization ion source. An HP 5-MS column (30 m60.25 mm,
0.25 mm) was used. Oven temperature was maintained at 150uC
for 5 min, and was then increased linearly to 300uC at a rate of
5uC/min. The temperature of the injector and the transfer line was
250uC. Helium was used as a carrier gas at a flow rate of 1 ml/min
in a constant flow mode. Mass spectra were acquired in a scan mode
(1.2 sec per scan). Sterols were identified on the basis of their mass
fragmentation patterns by comparing their spectra with those
collected in the Wiley database (The Wiley Registry of Mass
Spectral Data, 7th Edition, Wiley, 2000). In addition, the chemical
ionization method was used to confirm the molecular mass of the
sterols studied in one of the analyzed samples.
HPLC/MS analysis of glycerophospholipids
HPLC/MS analysis was carried out using a High-Performance
Liquid Chromatograph Prominence LC-20 (Shimadzu) coupled
with a tandem mass spectrometer 4000 Q TRAP (Applied
Biosystems Inc.). The mass spectrometer was equipped with an
electrospray (ESI) ion source (Turbo Ion Spray) and a triple
quadrupole/linear ion trap mass analyzer. HPLC separations were
performed using a 4.66150 mm Zorbax SIL RX (5 mm) column.
Solvent A was hexane : isopropanol (80:20) and solvent B was
isopropanol : water : triethylamine : formic acid (88:10:0.6:0.08). A
linear gradient was used in all measurements. The flow rate was
0.5 ml/min. Mass spectra were acquired in the positive and negative
ion mode. Nitrogen was used as the nebulizer and the curtain gas.
Results
Functional replacement of yeast HMG1 and HMG2 by
wild-type and mutated forms of the human HMGR gene
cDNAs encoding the wild-type and mutant forms of hHMGR gene
were expressed under the control of the yeast MET25 promoter in a
strain with deletions of both HMG1 and HMG2 (i.e. completely
devoid of HMGR activity). The wild-type and Q766H forms of the
enzyme restored viability of the yeast double deletion mutant,
demonstrating that the human proteins – even the Q766H mutant in
the catalytic domain – were catalytically active in yeast cells.
Relative mRNA quantification of the hHMGR gene
Treatment of cells with simvastatin had a differentiating effect
on the hHMGR mRNA level. After 24 h of growth, cells
expressing the wild-type gene for hHMGR displayed a 30%
increase in the relative mRNA level, while cells expressing a
mutated form of this enzyme displayed only a slight increase in the
mRNA level. Prolonged (48 h) treatment of cells with simvastatin
caused an increase in the level of hHMGR mRNA by about 20%
in cells expressing the mutated protein, whereas in cells expressing
the wild-type protein the increase was about 50%. We observed
similar effects of other statins on HMGR mRNA levels in cultures
of HepG2 cells treated with various statins (results not shown).
Lipids in wild-type yeast and in yeast expressing
wild-type or mutated hHMGR gene
To examine if changes in hHMGR gene expression level after
simvastatin treatment influence the lipid metabolic pathways we
analyzed the TLC separation patterns of lipids extracted from
wild-type yeast cells and from cells expressing the wild-type or
mutated form of hHMGR gene. As shown (Fig. 1 lanes 1, 3, 5) they
are similar insofar as all strains contain steryl esters, squalene,
triacylglycerols, and ergosterol and its precursors, though the
quantities of particular classes of lipids vary. In all cells that were
cultivated in the presence of simvastatin, we noticed a significant
drop in the level of sterol precursors – they could not be detected
on TLC plates in any strains (Fig. 1 lanes 2, 4, 6) indicating that
the ergosterol intermediates were efficiently converted to ergos-
terol. The decrease of the steryl esters is also clearly visible after
statin treatment (Fig. 1). The observation that ergosterol
precursors were readily used to form ergosterol led us to
investigate if statin treatment also induced the mobilization of
sterols stored in the form of steryl esters in lipid particles.
Confocal microscopy
Lipid particles were observed applying confocal microscopy. Nile
Red staining allows the visualization of membranes composed of
glycerophospholipids (red emission) and neutral lipids, triacyglycer-
ols and steryl esters, in lipid particles (green emission). As shown in
Fig. 2 wild-type cells incubated with buffer had lipid particles
containing neutral lipids that co-localized with phospholipids
(yellow), whereas cells treated with simvastatin displayed a decrease
in the intensity of both the green signal from steryl esters and the
Figure 1. TLC analysis of simple lipids. A significant drop in the
level of sterol precursors in cells cultivated in the presence of
simvastatin indicates that the ergosterol intermediates were efficiently
converted to ergosterol. The decrease of the steryl esters is also clearly
visible after statin treatment. Lanes 1, 3, 5 lipids from cells harbouring
the wild-type yeast, or the wild-type or mutated hHMGR gene,
respectively. Lanes 2, 4, 6 lipids from cells treated with simvastatin
harbouring the wild-type yeast, or the wild-type or mutated hHMGR
gene, respectively. Abbreviations: SQ squalene, SE steryl esters, TAG
triacylglycerols, EP ergosterol precursors, E ergosterol, L lanosterol, D
dolichol composed of 16 isoprene residues.
doi:10.1371/journal.pone.0008499.g001
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yellow signal from their co-localization with glycerophospholipids in
lipid particles.
Sterol precursor profiles for strains treated or not with
simvastatin
The results obtained during the analysis of lipids in strains
treated or not with simvastatin prompted us to perform a more
detailed analysis of ergosterol, sterol precursors and squalene
present in cells harbouring wild-type and mutated forms of the
hHMGR gene. Since steryl esters are the major source of ergosterol
precursors, we performed their alkaline hydrolysis. GC/MS
analyses revealed that in all the strains tested simvastatin treatment
reduced the cellular sterol pool. Interestingly, the level of
ergosterol was moderately lowered compared to that of total
sterols whereas the amount of squalene was significantly decreased
(Table 1). The strain harbouring the mutated form of the hHMGR
gene displayed the smallest changes in sterol intermediates after
statin treatment (Fig. 3).
Polar lipids in wild-type yeast and in yeast expressing the
wild-type or mutated hHMGR gene
TLC analysis of polar lipids from all the yeast strains
investigated showed that the patterns obtained are similar,
Figure 2. Nile Red staining of yeast lipid particles. Visualization of
membranes composed of glycerophospholipids (red emission) and neutral
lipids, triacyglycerols and steryl esters, in lipid particles (green emission).
Cells were cultured overnight. The media were then supplemented with
either 100 mM simvastatin or buffer and the cells were further grown with
shaking for two hours at 30uC. To localize neutral lipids and glyceropho-
spholipids in yeast cells, Nile Red staining was performed. Horizontal
panels: upper glycrophospholipids at 543 nm excitation and 610 nm
emission, middle neutral lipids at 488 nm excitation and 515/530 nm
emission, lower merge of above panels. Vertical panels: B cells cultivated in
buffer, S cells incubated for 2 h in buffer with simvastatin.
doi:10.1371/journal.pone.0008499.g002
Table 1. Decrease in sterols and squalene after simvastatin
treatment.
Strain Total sterols (%) Ergosterol (%) Squalene (%)
Wt 61 26 96
H 52 21 80
h 39 10 78
Lipids extracted from yeast cells were subjected to alkaline hydrolysis, purified
and analysed by GC/MS.
Wt, wild-type yeast; H, yeast harbouring wild-type hHMGR gene; h, yeast
harbouring the mutated hHMGR gene.
doi:10.1371/journal.pone.0008499.t001
Figure 3. GC/MS analysis of sterols from yeast cells. Changes in the level of ergosterol and its precursors in cells treated with simvastatin
depend on the mutation in the hHMGR gene. Panels 1, 3, 5 sterols from cells harbouring the wild-type yeast, or the wild-type or mutated hHMGR
gene, respectively. Panels 2, 4, 6 sterols from cells treated with simvastatin harbouring the wild-type yeast, or the wild-type or mutated hHMGR gene,
respectively. SQ squalene, Z zymosterol, E ergosterol, F fecosterol and isomers, L lanosterol and cholesta-8,14-dien 3-ol, 4.4-dimethyl (3’, 5;).
doi:10.1371/journal.pone.0008499.g003
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independently of the type of HMG reductase the cells harbour
(Fig. 4 lanes 1, 3, 5). Simvastatin treatment caused a decrease in
the level of synthesis of lipids apparently not connected with the
mevalonate pathway, such as glycerophospholipids (Fig. 4 lanes 2,
4, 6). Additional analyses, using two-dimensional chromatography
and HPLC/MS for the identification of the compounds separated,
demonstrated that the amounts of all major glycerophospholipids
were diminished by treatment with simvastatin (Fig. 5).
Discussion
Apart from their obvious hypocholesterolemic action, statins
have been shown to exert many cholesterol-independent, pleio-
tropic effects, related to inflammation, oxidative stress, thrombosis
and vascular function. However, molecular explanations for statin
pleiotropy are generally scarce. Although the effect of statin
treatment on the level of plasma cholesterol is well established,
little is known about the impact of HMGR inhibitors on cell lipid
metabolism.
Considering the fact that lipids are not only high-energy fuel
storage molecules and building blocks of cell membranes but are
also involved in modulating life processes in the cell, it is obvious
that their homeostasis is of major importance. In previous studies
we demonstrated that the yeast system is sensitive to statin
treatment in terms of yeast cell viability and growth rate [10]. In
the present study we observed that in yeast cells 24 h of
Figure 4. TLC analysis of complex lipids. Effect of simvastatin
treatment on glycerophospholipids, apparently not connected with
mevalonate pathway. Lanes 1, 3, 5 lipids from cells harbouring the wild-
type yeast, or the wild-type or mutated hHMGR gene, respectively.
Lanes 2, 4, 6 lipids from cells treated with simvastatin harbouring the
wild-type yeast, or the wild-type or mutated hHMGR gene, respectively.
Abbreviations: SQ squalene, SM simvastatin metabolites, PE phosphti-
dylethanolamine, GPL glycerophospholipids, SF sphingomyeline.
doi:10.1371/journal.pone.0008499.g004
Figure 5. Two dimensional chromatography of glycerophospholipids. The levels of all major glycerophospholipids were diminished by
treatment with simvastatin. Panels: 1, 3, 5 glycerophospholipids from cells harbouring the wild-type yeast, or the wild-type or mutated hHMGR gene,
respectively. Panels 2, 4, 6 glycerophospholipids from simvastatin treated cells harbouring the wild-type yeast, or the wild-type or mutated hHMGR
gene, respectively. Abbreviations: PC phosphtidylcholine, PE phosphtidylethanolamine, PS phosphatidylserine, PI phosphtidylinositol, PA phosphtidic
acid, LP lysoglycerophospholipid, FA fatty acid, NL neutral lipids.
doi:10.1371/journal.pone.0008499.g005
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simvastatin treatment induced expression of both wild-type and
mutated hHMGR genes. Moreover, we demonstrated that the
strength of this increase depends on the presence of a mutation in
the hHMGR gene. This is in accordance with other studies, which
showed increased expression of the hHMGR gene in HepG2 and L
cells, as well as in human skeletal muscle-like cells following statin
treatment [17,18].
After treatment with simvastatin efficient conversion of pre-
cursors was observed, especially squalene, to ergosterol (Fig. 1, 3).
Furthermore, within 2 h the signal intensity of steryl esters present
in lipid particles, which are structurally reminiscent of mammalian
lipoproteins particles [19] was significantly lowered suggesting that
they were mobilized to compensate for the level of free sterols.
Precursors are necessary for conversion to ergosterol that can
directly serve as a component for membrane biogenesis and is the
main constituent of the plasma membrane, similarly to cholesterol
in mammalian cells [20]. Among the strains investigated the one
with the mutated form of the hHMGR gene was the least sensitive
to simvastatin treatment both in expression level of the mRNA of
the hHMGR gene and in changes in the profile of sterol
intermediates. This can be explained by poorer binding of the
inhibitor to the active site of the mutated protein.
We postulate that inhibition of HMGR activity by statin
treatment may trigger an adaptive response in the cell. First, the
expression of the hHMGR gene is induced to compensate for the
enzyme’s inhibition. This finding is in accordance with the results
of Gerber [17], who suggest that induction of the hHMGR gene
compensates for the inhibition of the enzyme. Second, sterol
precursors of ergosterol are efficiently used to maintain the
physiological level of ergosterol.
Contrary to the effect of statin on plasma cholesterol level,
knowledge about the influence of statin therapy on lipid fractions,
such as phospholipids or sphingolipids is rather poor. Simvastatin
was shown to decrease de novo synthesis of phosphatidylcholine via
the cytidine diphosphate-choline pathway in HepG2 cell culture
[21]. Another in vitro study proved that in combination with lipid
restriction, atorvastatin reduced the phosphatidylserine pool by
50% [22]. Yet another study showed that pravastatin decreased
plasma concentration of total phospholipids and LDL-phospho-
lipids in hypercholesterolemic patients compared with the placebo
group [23]. Vecka reported that fluvastatin treatment decreased
the level of diphosphatidylglycerol in rat brain tissue [24]. The
authors postulate that the alterations observed in brain lipid
composition might be involved in genesis of neurological and
mental symptoms following statin therapy. We demonstrate here
that simvastatin treatment substantially decreased the amount of
glycerophospholipids in all yeast strain tested.
Using the yeast expression system, two significant phenomena
were detected. First, cells treated with simvastatin develop an
adaptive response compensating for the lower level of sterols. This
includes enhanced conversion of sterol precursors into ergosterol,
mobilization of steryl esters and increased expression of the HMGR
gene. Second, statins cause a substantial drop in the level of
glycerophospholipids. To conclude, using the yeast expression
system we demonstrated that statin treatment introduces signifi-
cant changes in cell lipid metabolism.
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